The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Trisomy 21 consistently activates the interferon response
Open accessAbstract
Although it is clear that trisomy 21 causes Down syndrome, the molecular events acting downstream of the trisomy remain ill defined. Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistently activated by trisomy 21 in human cells. Transcriptome analysis revealed that trisomy 21 activates the interferon transcriptional response in fibroblast and lymphoblastoid cell lines, as well as circulating monocytes and T cells. Trisomy 21 cells show increased induction of interferon-stimulated genes and decreased expression of ribosomal proteins and translation factors. An shRNA screen determined that the interferon-activated kinases JAK1 and TYK2 suppress proliferation of trisomy 21 fibroblasts, and this defect is rescued by pharmacological JAK inhibition. Therefore, we propose that interferon activation, likely via increased gene dosage of the four interferon receptors encoded on chromosome 21, contributes to many of the clinical impacts of trisomy 21, and that interferon antagonists could have therapeutic benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, both individuals with DS and mouse models of DS experience constitutive hyperactivation of interferon (IFN) signaling with signs of chronic inflammation and immune dysregulation,30,31,32,33,34,35,36,37,38,39,40 that could exacerbate the neuroinflammatory response.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“we reported the results of transcriptome analyses of four different cell types obtained from people with and without T21, which demonstrated that T21 causes widespread alterations in gene expression across the genome”
From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“including, most prominently, consistent activation of the interferon transcriptional response17”
From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“However, unbiased analyses using omics technology have recently revealed that T21 impacts gene expression across the genome39,74,143,156–159.”
From Consequences of trisomy 21 for brain development in Down syndrome (2024) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“people with DS present an increased IFN signaling likely driven by triplication of four of the six IFN receptors encoded on HSA21,36 rather than by massive elevation of the IFN ligands themselves as seen in interferonopathies,80 and this has been associated with chronic immune dysregulation.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [36]
The cited source says what the claim attributes to it.
In the citing paper
“Accumulating evidence supports the classification of DS as a multisystem interferonopathy (62, 63, 75).”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Given the dysregulated interferon signaling observed across multiple Ts21 organ systems (62, 63), we characterized the expression of interferon receptors, along with downstream interferon response genes.”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“our RNA-Seq analyses, combined with previously published RNA-Seq data (Letourneau et al., 2014;Sullivan et al., 2016), showed transcript levels for the analyzed acid hydrolases to be comparable in 2N and DS fibroblasts”
From Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) (2019) · cites this paper as Sullivan et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
RSeQC: quality control of RNA-seq experiments
Wang, L., Wang, S., & Li, W. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts356 · Cited by 2,753
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P. D., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,412
WebGestalt: an integrated system for exploring gene sets in various biological contexts
Zhang, B., Kirov, S. A., & Snoddy, J. R. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki475 · Cited by 1,803
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
Wang, J., Duncan, D. T., Shi, Z., & Zhang, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt439 · Cited by 1,512
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Flagged first, then by citations
1 of the 88 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 367
Dysregulated systemic metabolism in a Down syndrome mouse model
Sarver, D. C., Xu, C., Vélez, L. M., Aja, S. M., Jaffe, A. E., Seldin, M. M., Reeves, R. H., & Wong, G. W. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101666 · Cited by 32
Papendorf, J. J., Krüger, E., & Ebstein, F. (2022) · Cells · doi:10.3390/cells11091422 · Cited by 34
Struja, T., Kutz, A., Fischli, S., Meier, C., Müeller, B., Recher, M., & Schüetz, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0939-9 · Cited by 30
Consequences of trisomy 21 for brain development in Down syndrome
Russo, M. L., Sousa, A. M. M., & Bhattacharyya, A. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-024-00866-2 · Cited by 28
“However, unbiased analyses using omics technology have recently revealed that T21 impacts gene expression across the genome 39,74,143,156–159 .”
Lung Involvement in Systemic Juvenile Idiopathic Arthritis: A Narrative Review
Petrongari, D., Filippo, P. D., Misticoni, F., Basile, G., Pillo, S. D., Chiarelli, F., & Attanasi, M. (2022) · Diagnostics · doi:10.3390/diagnostics12123095 · Cited by 28
The transcriptome profile of human trisomy 21 blood cells
Antonaros, F., Zenatelli, R., Guerri, G., Bertelli, M., Locatelli, C., Vione, B., Catapano, F., Gori, A., Vitale, L., Pelleri, M. C., et al. (2021) · Human Genomics · doi:10.1186/s40246-021-00325-4 · Cited by 28
The Impact of Ageing on the CNS Immune Response in Alzheimer’s Disease
Chee, S. E. J., & Solito, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.738511 · Cited by 29
Ruxolitinib: A Review in Polycythaemia Vera
McKeage, K. (2015) · Drugs · doi:10.1007/s40265-015-0470-2 · Cited by 28
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Reiche, L., Küry, P., & Göttle, P. (2019) · Cells · doi:10.3390/cells8121591 · Cited by 28
Popadin, K. Y., Peischl, S., Garieri, M., Sailani, M. R., Letourneau, A., Santoni, F. A., Lukowski, S. W., Bazykin, G. A., Nikolaev, S. I., Meyer, D., et al. (2017) · Genome Research · doi:10.1101/gr.228411.117 · Cited by 29
Unraveling Down Syndrome: From Genetic Anomaly to Artificial Intelligence-Enhanced Diagnosis
Koul, A. M., Ahmad, F., Bhat, A., Aein, Q. U., Ahmad, A., Reshi, A. A., & Kaul, R.-U. R. (2023) · Biomedicines · doi:10.3390/biomedicines11123284 · Cited by 32
Ahmed, M. M., Wang, A. C., Elos, M. T., Chial, H. J., Sillau, S., Solano, D. A., Coughlan, C. M., Aghili, L., Anton, P. E., Markham, N. E., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105694 · Cited by 31
Klein, J. A., Li, Z., Rampam, S., Cardini, J., Ayoub, A., Shaw, P., Rachubinski, A. L., Espinosa, J. M., Zeldich, E., & Haydar, T. F. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.794675 · Cited by 27
Self-citationHow to Build a Fire: The Genetics of Autoinflammatory Diseases
Zhang, J., Lee, P. Y., Aksentijevich, I. A., & Zhou, Q. (2023) · Annual Review of Genetics · doi:10.1146/annurev-genet-030123-084224 · Cited by 28
Stankiewicz-Isidor syndrome: expanding the clinical and molecular phenotype
Isidor, B., Ebstein, F., Hurst, A., Vincent, M., Bader, I., Rudy, N. L., Cogne, B., Mayr, J., Brehm, A., Bupp, C., et al. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2021.09.005 · Cited by 24
Yu, Y. E., Xing, Z., Do, C., Pao, A., Lee, E. J., Krinsky‐McHale, S. J., Silverman, W. P., Schupf, N., & Tycko, B. (2020) · Progress in brain research · doi:10.1016/bs.pbr.2019.09.002 · Cited by 28
Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus
Grannò, S., Nixon‐Abell, J., Berwick, D. C., Tosh, J., Heaton, G., Almudimeegh, S., Nagda, Z., Rain, J., Zanda, M., Plagnol, V., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43820-4 · Cited by 29
Consequences of gaining an extra chromosome
Torres, E. M. (2023) · Chromosome Research · doi:10.1007/s10577-023-09732-w · Cited by 29
Mechanisms of Leukemia Evolution: Lessons from a Congenital Syndrome
Birger, Y., Shiloh, R., & Izraeli, S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.004 · Cited by 24
Challenges and Opportunities for Translation of Therapies to Improve Cognition in Down Syndrome
Lee, S. E., Duran-Martinez, M., Khantsis, S., Bianchi, D. W., & Guedj, F. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.10.001 · Cited by 25
Kuang, X., & Li, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.895961 · Cited by 23
State-of-the-art therapy for down syndrome
Lorenzon, N., Musoles‐Lleó, J., Turrisi, F., Gomis‐González, M., De La Torre, R., & Dierssen, M. (2023) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.15517 · Cited by 22
Mechanistic Analysis of Age-Related Clinical Manifestations in Down Syndrome
Chen, X., Xing, Z., Chen, Q.-D., Salvi, R., Zhang, X., Tycko, B., Mobley, W. C., & Yu, Y. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.700280 · Cited by 26
Dermatologic conditions in Down syndrome
Ryan, C., Vellody, K., Belazarian, L. T., & Rork, J. F. (2021) · Pediatric Dermatology · doi:10.1111/pde.14731 · Cited by 22
Vitale, L., Serpieri, V., Lauriola, M., Piovesan, A., Antonaros, F., Cicchini, E., Locatelli, C., Cocchi, G., Strippoli, P., & Caracausi, M. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28140 · Cited by 21
Prenatal histological, cellular, and molecular anomalies in trisomy 21 lung
Danopoulos, S., Bhattacharya, S., Deutsch, G. H., Nih, L. R., Slaunwhite, C. G., Mariani, T. J., & Alam, D. A. (2021) · The Journal of Pathology · doi:10.1002/path.5735 · Cited by 23
Dysregulation of the Immune System in a Natural History Study of 1299 Individuals with Down Syndrome
Gansa, W. H., da Rosa, J. M. C., Menon, K. M., Sazeides, C., Stewart, O., & Bogunovic, D. (2024) · Journal of Clinical Immunology · doi:10.1007/s10875-024-01725-6 · Cited by 21
Type I interferon signalling and interferon‐responsive microglia in health and disease
López‐Atalaya, J. P., & Bhojwani-Cabrera, A. M. (2025) · FEBS Journal · doi:10.1111/febs.70126 · Cited by 23
Ebola and Marburg Virus Infection in Bats Induces a Systemic Response
Jayaprakash, A. D., Ronk, A. J., Prasad, A. N., Covington, M. F., Stein, K. R., Schwarz, T. M., Hekmaty, S., Fenton, K. A., Geisbert, T. W., Basler, C. F., et al. (2020) · Viruses · doi:10.3390/v15020350 · Cited by 18
Down syndrome biobank consortium: a perspective
Aldecoa, I., Barroeta, I., Carroll, S. L., Fortea, J., Gilmore, A., Ginsberg, S. D., Guzman, S. J., Hamlett, E. D., Head, E., Perez, S. E., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13692 · Cited by 19
Balistreri, C. R., Ammoscato, C. L., Scola, L., Fragapane, T., Giarratana, R. M., Lio, D., & Piccione, M. (2020) · Genes · doi:10.3390/genes11121428 · Cited by 20
Down syndrome: insights into autoimmune mechanisms
Khor, B., & Buckner, J. H. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00970-0 · Cited by 19
Altable, M., & de la Serna, J. M. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04880-x · Cited by 20
Genetic Susceptibility to Periodontal Disease in Down Syndrome: A Case-Control Study
Fernández, M., de Coo, A., Quintela, I., García, E. V., Freitas, M. D., Posse, J. L., Dios, P. D., Blanco, J., Carracedo, Á., & Cruz, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126274 · Cited by 18
de Lagrán, M. M., Elizalde‐Torrent, A., Paredes, R., Clotet, B., & Dierssen, M. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17411 · Cited by 19
Ludwig, M. P., Galbraith, M. D., Eduthan, N. P., Hill, A. A., Clay, M. R., Tellez, C. M., Wilky, B. A., ELIAS, A. D., Espinosa, J. M., & Sullivan, K. D. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3173 · Cited by 18
Self-citationAdams, A. D., Guedj, F., & Bianchi, D. W. (2019) · Placenta · doi:10.1016/j.placenta.2019.10.002 · Cited by 18
Down Syndrome-Associated Arthritis (DA): Diagnostic and Management Challenges
Jones, J. T., Kitchen, J., & Talib, N. (2022) · Pediatric Health Medicine and Therapeutics · doi:10.2147/phmt.s282646 · Cited by 17
Hemophagocytic lymphohistocytosis in trisomy 21: successful treatment with interferon inhibition
Guild, A., Fritch, J., Patel, S. A., Reinhardt, A., & Acquazzino, M. A. (2022) · Pediatric Rheumatology · doi:10.1186/s12969-022-00764-w · Cited by 17
A single-cell transcriptome atlas of human euploid and aneuploid blastocysts
Wang, S., Leng, L., Wang, Q., Gu, Y., Li, J., An, Y., Deng, Q., Xie, P., Cheng, C., Chen, X., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01788-6 · Cited by 19
Precocious clonal hematopoiesis in Down syndrome is accompanied by immune dysregulation
Liggett, L. A., Galbraith, M. D., Smith, K. P., Sullivan, K. D., Granrath, R. E., Estrada, B. A. E., Kinning, K. T., Shaw, J. R., Rachubinski, A. L., Espinosa, J. M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003858 · Cited by 17
Self-citationJAK inhibition in Down Syndrome Regression Disorder
Rachubinski, A. L., Patel, L., Sannar, E. M., Kammeyer, R., Sanders, J. S., Estrada, B. A. E., Worek, K. R., Fidler, D. J., Santoro, J. D., & Espinosa, J. M. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578442 · Cited by 16
Self-citationIncreased risk of leukaemia in children with Down syndrome: a somatic evolutionary view
Hasaart, K., Bertrums, E. J. M., Manders, F., Goemans, B. F., & van Boxtel, R. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.6 · Cited by 16
Lee, H.-C., Yusof, H. H. M., Leong, M. P.-Y., Abidin, S. Z., Seth, E. A., Hewitt, C., Vidyadaran, S., Nordin, N., Scott, H. S., Cheah, P.-S., et al. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1580280 · Cited by 16
Pecze, L., & Szabó, C. (2021) · Mitochondrion · doi:10.1016/j.mito.2020.12.017 · Cited by 16
Schneider, D. J., Lynch, S. A., Gelinas, A. D., Ostroff, R. M., Rohloff, J. C., Williams, P., Janjić, N., & Drolet, D. W. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00007-5 · Cited by 14
Transcriptome Profiling Uncovers Potential Common Mechanisms in Fetal Trisomies 18 and 21
Volk, M., Maver, A., Hodžić, A., Lovrečić, L., & Peterlin, B. (2017) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2017.0123 · Cited by 15
Duval, N., Vacano, G. N., & Patterson, D. W. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00263 · Cited by 16
Bartesaghi, R., Vicari, S., & Mobley, W. C. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-041521-103641 · Cited by 18
Rubio, A. D., Hamilton, L. L., Bausch, M., Jin, M., Papetti, A. V., Jiang, P., & Yelamanchili, S. V. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10181-x · Cited by 17
The emerging concept of ANCA-associated vasculitis related to inborn errors of immunity
Triaille, C., Terrier, B., Hadchouel, A., Haddad, É., Vaglio, A., & Frémond, M. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103824 · Cited by 14
Evans, E. J., & DeGregori, J. V. (2022) · Journal of Clinical Investigation · doi:10.1172/jci161659 · Cited by 14
Self-citationBiphasic cell cycle defect causes impaired neurogenesis in down syndrome
Sharma, V., Nehra, S., Do, L. H., Ghosh, A., Deshpande, A. J., & Singhal, N. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1007519 · Cited by 14
Inherent genome instability underlies trisomy 21-associated myeloid malignancies
Chen, C.-C., Silberman, R. E., Ma, D., Perry, J. A., Khalid, D., Pikman, Y., Amon, A., Hemann, M. T., & Rowe, R. G. (2024) · Leukemia · doi:10.1038/s41375-024-02151-8 · Cited by 14
Donovan, M. G., Rachubinski, A. L., Smith, K. P., Araya, P., Waugh, K. A., Estrada, B. A. E., Britton, E. C., Lyford, H. R., Granrath, R. E., Schade, K. A., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114599 · Cited by 14
Self-citationMoon, J. E., & Lawrence, J. B. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111174 · Cited by 15
Nucleotide metabolism, leukodystrophies, and CNS pathology
Gavazzi, F., Gonzalez, C. D., Arnold, K., Swantkowski, M., Charlton, L., Modesti, N. B., Dar, A. A., Vanderver, A. L., Bennett, M. L., & Adang, L. A. (2024) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12721 · Cited by 17
Santoro, J. D., Jafarpour, S., Keehan, L. A., Khoshnood, M. M., Kazerooni, L., Boyd, N. K., Vogel, B. N., Nguyen, L., Manning, M. A., Nagesh, D., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-81819-8 · Cited by 13
Watson, L. A., & Meharena, H. S. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1198129 · Cited by 13
Down syndrome and leukemia: An insight into the disease biology and current treatment options
Barwe, S. P., Kolb, E. A., & Gopalakrishnapillai, A. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101154 · Cited by 13
Dynamic neuro-immune regulation of psychiatric risk loci in human neurons
Townsley, K. G., Lee, S. H., Williams, S., Cartwright, S., Cohen, S., Sen, A., Jia, M., Young, H. E., Dobbyn, L., Deans, M., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77114-x · Cited by 14
The Mutational Landscape of Myeloid Leukaemia in Down Syndrome
de Castro, C. P. M., Cadefau-Fabregat, M., & Cuartero, S. (2021) · Cancers · doi:10.3390/cancers13164144 · Cited by 16
Interferon receptor gene dosage determines diverse hallmarks of Down syndromePreprint
Waugh, K. A., Minter, R., Baxter, J. A., Chi, C., Tuttle, K. D., Eduthan, N. P., Galbraith, M. D., Kinning, K. T., Andrysík, Z., Araya, P., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.03.478982 · Cited by 14
Self-citationMolecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex
Risgaard, R. D., Hanthanan Arachchilage, K., Knaack, S. A., Hosseini, M., Chen, R. J., Kumarage, P., Schmidt, D. K., Huang, X., Sheng, J., Wang, C. J., et al. (2026) · Science · doi:10.1126/science.aea1549 · Cited by 12
Kim-Hellmuth, S., Hermann, M., Eilenberger, J., Ley‐Zaporozhan, J., Fischer, M., Hauck, F. H., Klein, C., Haas, N. A., Kappler, M., Hüebner, J., et al. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa148 · Cited by 12
Altered hepatic metabolism in Down syndrome
Dunn, L. N., Niemeyer, B. F., Eduthan, N. P., Schade, K. A., Waugh, K. A., Brown, C., Rachubinski, A. L., Timkovich, A. E., Orlicky, D. J., Galbraith, M. D., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2025.116835 · Cited by 11
Self-citationSantoro, J. D., Eduthan, N. P., Khoshnood, M. M., Jafarpour, S., Boyd, N. K., Vogel, B. N., Nguyen, L., Kazerooni, L., Britton, E. C., Lyford, H. R., et al. (2025) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.52299 · Cited by 11
Self-citationExpanding the clinical and neuroimaging features of post-varicella arteriopathy of childhood
Bertamino, M., Signa, S., Veneruso, M., Prato, G., Caorsi, R., Losurdo, G., Teutonico, F., Esposito, S., Formica, F., Tovaglieri, N., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10606-6 · Cited by 11
Rafferty, K. A., Archer, K. J., Turner, K. C., Brown, R. C., & Jackson‐Cook, C. K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254806 · Cited by 12
Rakasiwi, T., Ryan, C., Stein, A., Vu, A., Dykman, M., Shah, I., Reilly, C. C., Brokamp, G., Mologousis, M. A., Komishke, B., et al. (2024) · Pediatric Dermatology · doi:10.1111/pde.15757 · Cited by 10
A Trisomy 21 Lung Cell AtlasPreprint
Bhattacharya, S., Cherry, C. L., Deutsch, G. H., Glass, I. A., Mariani, T. J., Alam, D. A., & Danopoulos, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.03.30.534839 · Cited by 10
Rusu, B., Kukreja, B., Wu, T., Dan, S. J., Feng, M. Y., & Kalish, B. T. (2023) · eNeuro · doi:10.1523/eneuro.0147-23.2023 · Cited by 9
Integrated analysis of immunometabolic interactions in Down syndrome
Gillenwater, L. A., Galbraith, M. D., Rachubinski, A. L., Eduthan, N. P., Sullivan, K. D., Espinosa, J. M., & Costello, J. C. (2024) · Science Advances · doi:10.1126/sciadv.adq3073 · Cited by 9
Self-citationMolecular cartography of the human down syndrome and trisomic mouse brain
Feng, M. Y., Cao, W., Tahmasian, N., Kukreja, B., Li, G. L., Rusu, B., Youn, J., & Kalish, B. T. (2025) · Nature Communications · doi:10.1038/s41467-025-63752-0 · Cited by 9
Lazzarino, G., Amorini, A. M., Mangione, R., Saab, M. W., Stasio, E. D., Rosa, M. D., Tavazzi, B., Lazzarino, G., Onder, G., & Carfì, A. (2022) · Antioxidants · doi:10.3390/antiox11061208 · Cited by 9
Blood counts in children with Down syndrome
Harvey, S., Wolter‐Warmerdam, K., Hickey, F. J., Daniels, D. A., DomBourian, M. G., Ambruso, D. R., & McKinney, C. M. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30002 · Cited by 9
Consequences of trisomy syndromes – 21 and beyond
Krivega, M., & Štorchová, Z. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.11.004 · Cited by 9
Single‐cell landscape analysis reveals systematic senescence in mammalian Down syndrome
Chen, Y., Xiao, Y., Zhang, Y., Wang, R., Wang, F., Gao, H., Liu, Y., Zhang, R., Sun, H., Zhou, Z., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1310 · Cited by 9
Malignant progression of preleukemic disorders
Hall, T., Gurbuxani, S. K., & Crispino, J. D. (2024) · Blood · doi:10.1182/blood.2023020817 · Cited by 9
Granholm, A., Englund, E. M., Gilmore, A., Head, E., Yong, W. H., Perez, S. E., Guzman, S. J., Hamlett, E. D., & Mufson, E. J. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02743-9 · Cited by 11
Wagemann, O., Nübling, G., Martínez-Murcia, F. J., Wlasich, E., Loosli, S. V., Sandkühler, K., Stockbauer, A., Prix, C., Katzdobler, S., Petrera, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70040 · Cited by 9
Consequences of mitotic failure – The penalties and the rewards
Štorchová, Z. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.03.007 · Cited by 9
Autophagy is a promising process for linking inflammation and redox homeostasis in Down syndrome
Ma, X., Li, W., Ma, J., Han, Z., Deng, S., & Wang, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1491563 · Cited by 9
Kynurenine pathway metabolite alterations in Down syndrome and Alzheimer's disease
dos Reis, R. G., Singulani, M. P., Forlenza, O. V., Gattaz, W. F., & Talib, L. L. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70197 · Cited by 8
Mazzarino, R. C., Barešová, V., Zikánová, M., Duval, N., Wilkinson, T. G., Patterson, D., & Vacano, G. N. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247227 · Cited by 8
Colvin, K. L., Nguyen, K., Boncella, K. L., Goodman, D. M., Elliott, R. J., Harral, J. W., Bilodeaux, J., Smith, B. J., & Yeager, M. E. (2023) · Genes · doi:10.3390/genes14091819 · Cited by 8
Uguagliati, B., & Grilli, M. (2024) · Cells · doi:10.3390/cells13242037 · Cited by 8
Chorvinsky, E. A., Bhattacharya, S., Bera, B. S., Welham, A., Ismat, K., Lawlor, C. M., Preciado, D. A., Gómez, J. L., Morizono, H., Pillai, D. K., et al. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2025-0068oc · Cited by 8
Antiviral Immune Response in Alzheimer’s Disease: Connecting the Dots
Roy, E. R., & Cao, W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.577744 · Cited by 8
Araya, P., Niemeyer, B., Schade, K., Dunn, L. N., Waugh, K., Busquet, N., Brindley, C., Brown, C., Winkler, C., Lyford, H. R., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113130 · Cited by 7
Self-citationAlldred, M. J., Ibrahim, K. W., Pidikiti, H., Chiosis, G., Mufson, E. J., Stutzmann, G. E., & Ginsberg, S. D. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01891-z · Cited by 7
Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome
Cozzolino, K., Sanford, L., Hunter, S., Molison, K., Erickson, B., Courvan, M. C., Jones, T., Ajit, D., Galbraith, M. D., Espinosa, J. M., et al. (2024) · eLife · doi:10.7554/elife.100197.3 · Cited by 9
Self-citationSafety and tolerability of intravenous immunoglobulin infusion in Down syndrome regression disorder
Santoro, J. D., Jafarpour, S., Khoshnood, M. M., Boyd, N. K., Vogel, B. N., Nguyen, L., Saucier, L. E., Partridge, R., Tiongson, E., Ramos-Platt, L. M., et al. (2024) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63524 · Cited by 7
Alldred, M. J., Pidikiti, H., Ibrahim, K. W., Lee, S. H., Heguy, A., Hoffman, G. E., Roussos, P., Wısnıewskı, T., Węgiel, J., Stutzmann, G. E., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02768-0 · Cited by 8
Taksande, A. M., Pujari, D., Jameel, P. Z., Taksande, B., & Meshram, R. J. (2021) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v10.i6.177 · Cited by 7
Adverse childhood experiences and the development of Down syndrome regression disorder
Wang, S., Patel, L., Sannar, E. M., Khoshnood, M. M., Boyd, N. K., Mendez, L., Spinazzi, N. A., Quinn, E. A., Rafii, M. S., & Santoro, J. D. (2023) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63199 · Cited by 7
Lee, S. E., Baxter, L. L., Duran, M. I., Morris, S. D., Mosley, I. A., Fuentes, K., Pennings, J. L. A., Guedj, F., & Bianchi, D. W. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae160 · Cited by 7
Jana, B., & Acharyya, S. (2022) · Soft Computing · doi:10.1007/s00500-022-07515-9 · Cited by 6
Inverse and Proportional Trans Modulation of Gene Expression in Human Aneuploidies
Zhang, S., Wang, R., Zhang, L., Birchler, J. A., & Sun, L. (2024) · Genes · doi:10.3390/genes15050637 · Cited by 6
De novo variants in immune regulatory genes in Down syndrome regression disorder
Jafarpour, S., Banerjee, A. K., Khoshnood, M. M., Vogel, B. N., Boyd, N. K., Nguyen, L., Partridge, R., Santoro, S. L., Gombolay, G. Y., Fisher, K. S., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-024-12521-y · Cited by 6
Metadata
- Authors
- Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., DeGregori, J., & Espinosa, J. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Colorado Anschutz (US)
- Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, United States
- Corresponding author
- Sullivan, Kelly D
- ORCID
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2016-07-29
- Volume
- 5
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC5012864
- OpenAlex
- W2487528628
- Cited by
- 362
- References
- 88
- Citations by year
- 2026: 50 · 2025: 41 · 2024: 58 · 2023: 40 · 2022: 40 · 2021: 42 · 2020: 36 · 2019: 21 · 2018: 14 · 2017: 16 · 2016: 3
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- eLife (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Colorado (Linda Crnic Institute for Down Syndrome)
- Howard Hughes Medical Institute
- National Institutes of Health (R01CA117907, P30CA046934-27)
- National Science Foundation (MCB-1243522)
- Anna and John J. Sie Foundation
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Keywords
- Down syndrome, interferon signaling, interferon-stimulated genes, gene dosage, interferon receptor, JAK1, TYK2, ribosomal proteins, translation (biology), cell proliferation, shRNA screen, JAK inhibition, transcriptome
- MeSH terms
- Cells, Cultured, Down Syndrome, Fibroblasts, Humans, Immunity, Innate, Interferons, Monocytes, T-Lymphocytes, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
